Literature DB >> 10874641

CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.

A Ruiz1, S Puig, J Malvehy, C Lázaro, M Lynch, A M Gimenez-Arnau, L Puig, J Sánchez-Conejo, X Estivill, T Castel.   

Abstract

The CDKN2A gene has been implicated in cutaneous malignant melanoma (CMM) in about 40% of families with linkage to chromosome 9p21, while a small proportion of families have mutations in the CDK4 gene. In order to estimate the importance of these genes in the predisposition to CMM in Spanish families and patients we have analysed, by SSCA, a total of 56 subjects belonging to 34 CMM families, and nine patients with multiple CMM and other neoplasia. We have detected germline CDKN2A mutations in six out of the 34 families (17%). A frameshift mutation (358delG) and four missense mutations (G59V, G101W (two cases), D84Y, and R87W) were identified. Five CMM patients from different families (14%) carried the A148T variant, which is known not to affect p16 activity. No mutations were detected in the patients with multiple CMM or other neoplasms. We have not found mutations either in exon 1 beta of the CDKN2A gene or in exon 2A of CDK4. Linkage analysis of the 9p21 region showed exclusion for one of the families for CMM and for four families for CMM/dysplastic naevi. This study indicates a small role for CDKN2A in Spanish CMM families and suggests that other genes are also responsible for CMM predisposition.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10874641      PMCID: PMC1734379     

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  9 in total

1.  A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.

Authors:  P Ciotti; J P Struewing; M Mantelli; A Chompret; M F Avril; P L Santi; M A Tucker; G Bianchi-Scarrà; B Bressac-de Paillerets; A M Goldstein
Journal:  Am J Hum Genet       Date:  2000-06-22       Impact factor: 11.025

2.  Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.

Authors:  Miriam Potrony; Joan Anton Puig-Butillé; Paula Aguilera; Celia Badenas; Cristina Carrera; Josep Malvehy; Susana Puig
Journal:  J Am Acad Dermatol       Date:  2014-07-24       Impact factor: 11.527

3.  Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.

Authors:  Alisa M Goldstein; May Chan; Mark Harland; Nicholas K Hayward; Florence Demenais; D Timothy Bishop; Esther Azizi; Wilma Bergman; Giovanna Bianchi-Scarra; William Bruno; Donato Calista; Lisa A Cannon Albright; Valerie Chaudru; Agnes Chompret; Francisco Cuellar; David E Elder; Paola Ghiorzo; Elizabeth M Gillanders; Nelleke A Gruis; Johan Hansson; David Hogg; Elizabeth A Holland; Peter A Kanetsky; Richard F Kefford; Maria Teresa Landi; Julie Lang; Sancy A Leachman; Rona M MacKie; Veronica Magnusson; Graham J Mann; Julia Newton Bishop; Jane M Palmer; Susana Puig; Joan A Puig-Butille; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Linda Whitaker; Emanuel Yakobson
Journal:  J Med Genet       Date:  2006-08-11       Impact factor: 6.318

Review 4.  Selection criteria for genetic assessment of patients with familial melanoma.

Authors:  Sancy A Leachman; John Carucci; Wendy Kohlmann; Kimberly C Banks; Maryam M Asgari; Wilma Bergman; Giovanna Bianchi-Scarrà; Teresa Brentnall; Brigitte Bressac-de Paillerets; William Bruno; Clara Curiel-Lewandrowski; Femke A de Snoo; Tadeusz Debniak; Marie-France Demierre; David Elder; Alisa M Goldstein; Jane Grant-Kels; Allan C Halpern; Christian Ingvar; Richard F Kefford; Julie Lang; Rona M MacKie; Graham J Mann; Kurt Mueller; Julia Newton-Bishop; Håkan Olsson; Gloria M Petersen; Susana Puig; Darrell Rigel; Susan M Swetter; Margaret A Tucker; Emanuel Yakobson; John A Zitelli; Hensin Tsao
Journal:  J Am Acad Dermatol       Date:  2009-10       Impact factor: 11.527

Review 5.  Reconstructing skin cancers using animal models.

Authors:  Michael D Gober; Hasan M Bashir; John T Seykora
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

6.  A comparison of CDKN2A mutation detection within the Melanoma Genetics Consortium (GenoMEL).

Authors:  Mark Harland; Alisa M Goldstein; Kairen Kukalizch; Claire Taylor; David Hogg; Susana Puig; Celia Badenas; Nelleke Gruis; Jeanet ter Huurne; Wilma Bergman; Nicholas K Hayward; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Maria Teresa Landi; Giovanna Bianchi Scarra; Paola Ghiorzo; Peter A Kanetsky; David Elder; Graham J Mann; Elizabeth A Holland; D Timothy Bishop; Julia Newton Bishop
Journal:  Eur J Cancer       Date:  2008-04-03       Impact factor: 9.162

7.  CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.

Authors:  G Della Torre; B Pasini; S Frigerio; R Donghi; D Rovini; D Delia; G Peters; T J Huot; G Bianchi-Scarra; F Lantieri; M Rodolfo; G Parmiani; M A Pierotti
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

8.  A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.

Authors:  A M Goldstein; L Liu; M G Shennan; D Hogg; M A Tucker; J P Struewing
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

Review 9.  CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition.

Authors:  Sock Hoai Chan; Jianbang Chiang; Joanne Ngeow
Journal:  Hered Cancer Clin Pract       Date:  2021-03-25       Impact factor: 2.857

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.